|
|
|
Grand Challenges Explorations fosters creative projects that show great promise to improve the health of people in the developing world. Initial grants are awarded two times a year, and successful projects have the opportunity to receive additional funding of up to $1 million.
On May 10, 2010, the Gates Foundation announced that 78 new global health projects received Grand Challenges Explorations grants. Learn more about these below. Round 5 grants will be announced in October 2010.
To review all 340 Explorations projects, select "Show All Rounds" in the Round drop-down menu. |
|
|
|
|
|
|
|
|
|
|
|
|
Showing Grants 1 to 10 of 16 | | A Self-Adjuvanting Vaccine for ST-ETEC | | | Roy Robins-Browne, University of Melbourne, Melbourne, Victoria, Australia - AU |
| | | | | Enterotoxigenic E. coli (ETEC) is the leading cause of diarrhea in the developing world. Roy Robins-Browne, of the University of Melbourne, in Australia will evaluate the effectiveness of a prototype vaccine that combines enterotoxin of E. coli (which lacks immunogenicity by itself) with another epitope to attract helper T cells and a lipid adjuvant to ensure delivery of the antigen directly into the cell. | | A VLP-Based Phage Display System for HIV Vaccine Discovery | | | Bryce Chackerian, University of New Mexico, Albuquerque, NM, United States - US |
| | | | | Bryce Chackerian and David Peabody at the University of New Mexico in the U.S. have developed a new phage display system based on highly immunogenic virus-like particles (VLPs), and will utilize this new system as a platform to identify new vaccines that induce broadly neutralizing antibodies against HIV. | | Development of a Glycan Vaccine for Tuberculosis | | | Carlos Rivera-Marrero, Emory University School of Medicine, Atlanta, GA, United States - US |
| | | | | Glycans are an important component of surface molecules in tuberculosis but their role in protective immunity is still largely unexplored. Carlos Rivera-Marrero and Richard D. Cumming of Emory University in the U.S. will develop high-throughput glycan microarrays to identify glycan antigens, determine their chemical structure, and design glycan-peptide vaccines for future testing. | | Development of a Synthetic Anti-Toxic Vaccine for Malaria | | | Louis Schofield, The Walter and Eliza Hall Institute, Melbourne, Victoria, Australia - AU |
| | | | | Louis Schofield of The Walter and Eliza Hall Institute in Australia will develop a synthetic saccharide-conjugated vaccine that would provide immunity against GPI, a toxin produced by the malaria parasite that is a major determinant in the severity and fatality of the disease. | | Exosomes as a Novel M. tuberculosis Vaccine | | | Jeff Schorey, University of Notre Dame, Notre Dame, IN, United States - US |
| | | | | Jeff Schorey of the University of Notre Dame in the U.S. will evaluate the use of exosomes, which are small membrane vesicles released from macrophages infected with Mycobacterium tuberculosis, as a new platform for TB vaccines. Exosomes contain proteins and glycolipids that can elicit a robust innate and acquired immune response. | | Experimental Human Carriage of Pneumococci | | | Stephen Gordon, Liverpool School of Tropical Medicine, Liverpool, United Kingdom - GB |
| | | | | Because human carriage of pneumococcus usually results in improved immunity to future infections without any development of disease, Stephen Gordon of the Liverpool School of Tropical Medicine in the UK will utilize an intranasal inoculation with a safe strain of the bacteria to study the mechanisms of mucosal immunity in the lungs and to explore the potential for a vaccine based on his findings.
| | How to Break B Tolerance and Induce HIV-Protective Antibodies to CCR5 | | | Lucia Lopalco, San Raffaele Scientific Institute, Milan, Italy - IT |
| | | | | HIV uses the CCR5 co-receptor protein found in mammals as a major pathway to enter target cells. Because some patients who are exposed, yet resistant, to the virus, or have HIV but do not ever progress to AIDS can exhibit the presence of CCR5 internalizing antibodies, Lucia Lopalco of the San Raffaele Scientific Institute in Italy will attempt to generate “anti-self” antibodies against CCR5 to knock out protein’s co-receptor and effectively block HIV entry. | | HSV-2 Vaccine Vector to Encode Multiple HIV T-cell Epitopes | | | Lynda Morrison, St. Louis University, St. Louis, MO, United States - US |
| | | | | Lynda Morrison of St. Louis University in the U.S. will develop a vaccine vector based on a prototype vaccine for herpes simplex virus 2 (HSV-2) that encodes multiple CD8 T cell epitopes from HIV proteins, and test its ability to stimulate a robust CD8 T cell response against HIV. | | Hydrocarbon-Stapled GP41 Immunogens | | | Loren Walensky, Dana-Farber Cancer Institute, Boston, MA, United States - US |
| | | | | Loren Walensky of the Dana-Farber Cancer Institute in the U.S. will apply a new chemical technology to engineer structurally stable HIV-1 antigens for vaccine development. Walensky will test whether preserving the critical biologically active shape of HIV-1 polypeptides will yield neutralizing antibodies upon vaccination with his laboratory’s synthetic immunogens. | | Immune Reinforcing Attenuated Whole-Sporozoite as Vaccine | | | Guang-hong Tan, Hainan Provincial Key Laboratory of Tropical Medicine, Haikou, Hainan, China - CN |
| | | | | Guang-hong Tan of Hainan Provincial Key Laboratory of Tropical Medicine in China seeks to create a next-generation malaria vaccine by deleting a gene responsible for parasite development in the liver adding a new gene which attracts dendritic cells to the infection site. Using this modified sporozoite in a vaccine could produce a limited infection that, at the same time, induces a strong immune response against malaria. |
1
- 10  |
|
|
|
|
|
|
|